Cargando…

A Methodological Safe-by-Design Approach for the Development of Nanomedicines

Safe-by-Design (SbD) concepts foresee the risk identification and reduction as well as uncertainties regarding human health and environmental safety in early stages of product development. The EU’s NANoREG project and further on the H2020 ProSafe initiative, NanoReg2, and CALIBRATE projects have dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmutz, Mélanie, Borges, Olga, Jesus, Sandra, Borchard, Gerrit, Perale, Giuseppe, Zinn, Manfred, Sips, Ädrienne A. J. A. M, Soeteman-Hernandez, Lya G., Wick, Peter, Som, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145422/
https://www.ncbi.nlm.nih.gov/pubmed/32300587
http://dx.doi.org/10.3389/fbioe.2020.00258
_version_ 1783519997899833344
author Schmutz, Mélanie
Borges, Olga
Jesus, Sandra
Borchard, Gerrit
Perale, Giuseppe
Zinn, Manfred
Sips, Ädrienne A. J. A. M
Soeteman-Hernandez, Lya G.
Wick, Peter
Som, Claudia
author_facet Schmutz, Mélanie
Borges, Olga
Jesus, Sandra
Borchard, Gerrit
Perale, Giuseppe
Zinn, Manfred
Sips, Ädrienne A. J. A. M
Soeteman-Hernandez, Lya G.
Wick, Peter
Som, Claudia
author_sort Schmutz, Mélanie
collection PubMed
description Safe-by-Design (SbD) concepts foresee the risk identification and reduction as well as uncertainties regarding human health and environmental safety in early stages of product development. The EU’s NANoREG project and further on the H2020 ProSafe initiative, NanoReg2, and CALIBRATE projects have developed a general SbD approach for nanotechnologies (e.g., paints, textiles, etc.). Based on it, the GoNanoBioMat project elaborated a methodological SbD approach (GoNanoBioMat SbD approach) for nanomedicines with a focus on polymeric nanobiomaterials (NBMs) used for drug delivery. NBMs have various advantages such as the potential to increase drug efficacy and bioavailability. However, the nanoscale brings new challenges to product design, manufacturing, and handling. Nanomedicines are costly and require the combination of knowledge from several fields. In this paper, we present the GoNanoBioMat SbD approach, which allows identifying and addressing the relevant safety aspects to address when developing polymeric NBMs during design, characterization, assessment of human health and environmental risk, manufacturing and handling, and combines the nanoscale and medicine field under one approach. Furthermore, regulatory requirements are integrated into the innovation process.
format Online
Article
Text
id pubmed-7145422
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71454222020-04-16 A Methodological Safe-by-Design Approach for the Development of Nanomedicines Schmutz, Mélanie Borges, Olga Jesus, Sandra Borchard, Gerrit Perale, Giuseppe Zinn, Manfred Sips, Ädrienne A. J. A. M Soeteman-Hernandez, Lya G. Wick, Peter Som, Claudia Front Bioeng Biotechnol Bioengineering and Biotechnology Safe-by-Design (SbD) concepts foresee the risk identification and reduction as well as uncertainties regarding human health and environmental safety in early stages of product development. The EU’s NANoREG project and further on the H2020 ProSafe initiative, NanoReg2, and CALIBRATE projects have developed a general SbD approach for nanotechnologies (e.g., paints, textiles, etc.). Based on it, the GoNanoBioMat project elaborated a methodological SbD approach (GoNanoBioMat SbD approach) for nanomedicines with a focus on polymeric nanobiomaterials (NBMs) used for drug delivery. NBMs have various advantages such as the potential to increase drug efficacy and bioavailability. However, the nanoscale brings new challenges to product design, manufacturing, and handling. Nanomedicines are costly and require the combination of knowledge from several fields. In this paper, we present the GoNanoBioMat SbD approach, which allows identifying and addressing the relevant safety aspects to address when developing polymeric NBMs during design, characterization, assessment of human health and environmental risk, manufacturing and handling, and combines the nanoscale and medicine field under one approach. Furthermore, regulatory requirements are integrated into the innovation process. Frontiers Media S.A. 2020-04-02 /pmc/articles/PMC7145422/ /pubmed/32300587 http://dx.doi.org/10.3389/fbioe.2020.00258 Text en Copyright © 2020 Schmutz, Borges, Jesus, Borchard, Perale, Zinn, Sips, Soeteman-Hernandez, Wick and Som. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Schmutz, Mélanie
Borges, Olga
Jesus, Sandra
Borchard, Gerrit
Perale, Giuseppe
Zinn, Manfred
Sips, Ädrienne A. J. A. M
Soeteman-Hernandez, Lya G.
Wick, Peter
Som, Claudia
A Methodological Safe-by-Design Approach for the Development of Nanomedicines
title A Methodological Safe-by-Design Approach for the Development of Nanomedicines
title_full A Methodological Safe-by-Design Approach for the Development of Nanomedicines
title_fullStr A Methodological Safe-by-Design Approach for the Development of Nanomedicines
title_full_unstemmed A Methodological Safe-by-Design Approach for the Development of Nanomedicines
title_short A Methodological Safe-by-Design Approach for the Development of Nanomedicines
title_sort methodological safe-by-design approach for the development of nanomedicines
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145422/
https://www.ncbi.nlm.nih.gov/pubmed/32300587
http://dx.doi.org/10.3389/fbioe.2020.00258
work_keys_str_mv AT schmutzmelanie amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT borgesolga amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT jesussandra amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT borchardgerrit amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT peralegiuseppe amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT zinnmanfred amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT sipsadrienneajam amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT soetemanhernandezlyag amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT wickpeter amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT somclaudia amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT schmutzmelanie methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT borgesolga methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT jesussandra methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT borchardgerrit methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT peralegiuseppe methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT zinnmanfred methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT sipsadrienneajam methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT soetemanhernandezlyag methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT wickpeter methodologicalsafebydesignapproachforthedevelopmentofnanomedicines
AT somclaudia methodologicalsafebydesignapproachforthedevelopmentofnanomedicines